SCHEMBL7583115

SCHEMBL7583115

OCCC(CCO)NCO

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.33
DPP4 P27487 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12471536 0.75 LMNA (0.36) THRB
SCHEMBL20599906 0.75 PTPN1 (0.35)
SCHEMBL7951950 0.72
SCHEMBL8940848 0.71 GGT1 (0.35)
SCHEMBL88810 0.69 TSHR (0.32)
SCHEMBL5128930 0.69
SCHEMBL23015998 0.68
SCHEMBL20459207 0.68 LMNA (0.50)
Hydrochloric Acid SCHEMBL7032035 0.68 TSHR (0.30)
SCHEMBL14405035 0.67 LMNA (0.46) THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1245249-A2 Use of a cationic amphipathic compound as a transfection agent, vaccine additive or drug Aventis Pasteur (FR) 2002-10-02 EP disclosed
US-6124270-A IMMUNOLOGY, GENE THERAPY PASTEUR MERIEUX SERUMS ET VACCINS (FR) 2000-09-26 US disclosed
EP-0769942-A1 USE OF A CATIONIC AMPHIPATHIC COMPOUND AS A TRANSFECTION AGENT, VACCINE ADDITIVE OR DRUG PASTEUR MERIEUX SERUMS ET VACCINS (FR) 1997-05-02 EP disclosed
WO-1996032102-A1 USE OF A CATIONIC AMPHIPATHIC COMPOUND AS A TRANSFECTION AGENT, VACCINE ADDITIVE OR DRUG PASTEUR MERIEUX SERUMS ET VACCINS (FR) 1996-10-17 WO disclosed